Clinical Trial Update: Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial of fludarabine phosphate, rituximab, and bevacizumab in relapsed or refractory B-cell chronic lymphocytic leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bevacizumab (bevacizumab)
• Fludarabine phosphate (Fludarabine phosphate)
• Rituximab (rituximab)

Snippet

Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Conditions: B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 2 | Status: WITHDRAWN